CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsLow earnings quality
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
368.27MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
1.43xvs all stocks
52-Week Change
18.43%vs all stocks
Market Capitalization
368.27MUSDvs all stocks (USD)
Enterprise Value
172.38MUSDvs all stocks (USD)
Forward P/E
-3.77xvs Biotechnology peers
Price to Book (MRQ)
1.50xvs Biotechnology peers
Enterprise to EBITDA
-1.77xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-32.50%vs Biotechnology peers
Return on Equity (TTM)
-54.75%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
-62.33MUSDvs all stocks (USD)
EBITDA (TTM)
-97.18MUSDvs all stocks (USD)
Net Income (TTM)
-87.50MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-97.99MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-67.34MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-109.26MUSDvs all stocks (USD)
Pre-tax Income
-99.96MUSDFY2025 · Dec 31, 2025Income Tax Expense
0.00USDFY2025 · Dec 31, 2025Net Income
-99.96MUSDFY2025 · Dec 31, 2025EBIT
-99.75MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-101.07MUSDFY2025 · Dec 31, 2025Research & Development
63.80MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
45.46MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
6.13MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
206.00KUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-99.96MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-88.82MUSDFY2025 · Dec 31, 2025Free Cash Flow
-89.21MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.08M of depreciation against 397K of capital expenditure, and its own free-cash-flow line reads -98.96M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
66.25MUSDFY2025 · Dec 31, 2025Interest Paid
104.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-99.96MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.08MUSDFY2025 · Dec 31, 2025Stock-based Compensation
12.13MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-1.56MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.50MUSDFY2025 · Dec 31, 2025Capital Expenditures
-397.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-195.38MUSDFY2025 · Dec 31, 2025Sale of Investments
105.53MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-90.25MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-533.00KUSDFY2025 · Dec 31, 2025Common Stock Repurchase
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-16.75MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
216.74MUSDFY2025 · Dec 31, 2025Shares Outstanding
74.09MSharesUpdated Jul 19, 2026Float Shares
47.33MSharesUpdated Jul 19, 2026Shares Short
16.13MSharesUpdated Jul 19, 2026Short Ratio
16.87daysvs all stocks
Short % of Shares Outstanding
24.15%vs all stocks
% Held by Insiders
0.60%vs all stocks
% Held by Institutions
114.50%vs all stocks
Total Cash (MRQ)
193.04MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
2.46USDUpdated Jul 19, 2026Total Debt (MRQ)
7.37MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0318xvs Biotechnology peers
Current Ratio (MRQ)
14.16xvs Biotechnology peers
Book Value per Share (MRQ)
3.13USDUpdated Jul 19, 2026Total Assets
268.69MUSDvs all stocks (USD)
Total Current Assets
188.39MUSDFY2025 · Dec 31, 2025Total Liabilities
22.02MUSDFY2025 · Dec 31, 2025Total Non-current Assets
80.30MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
5.21MUSDFY2025 · Dec 31, 2025Total Current Liabilities
16.81MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
63.00MUSDFY2025 · Dec 31, 2025Other Short-term Investments
118.77MUSDFY2025 · Dec 31, 2025Accounts Payable
4.86MUSDFY2025 · Dec 31, 2025Short-term Debt
2.67MUSDFY2025 · Dec 31, 2025Other Current Liabilities
73.00KUSDFY2025 · Dec 31, 2025Long-term Debt
5.21MUSDFY2025 · Dec 31, 2025Common Stock (Book)
7.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-380.13MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
246.67MUSDvs all stocks (USD)
Treasury Stock
17.00KUSDFY2025 · Dec 31, 202552-Week Low
3.60USDUpdated Jul 19, 202652-Week High
10.99USDUpdated Jul 19, 202652-Week Change
18.43%vs all stocks
Beta
1.43xvs all stocks
50-Day MA
4.93USDUpdated Jul 19, 2026200-Day MA
7.09USDUpdated Jul 19, 2026Avg 10-Day Volume
831.35KSharesUpdated Jul 19, 2026Avg 30-Day Volume
927.44KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.12USDUpdated Jul 19, 2026Other Income / Expense
3.37MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.64
Altman Z-Score 7.6: safe zoneNotable
Altman Z-Score: 7.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Aska Pharmaceutical Holdings Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Fennec Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Universal Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
X4 Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shengda Bio-Pharm Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Nanjing Xinjiekou Department Store Co. Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Halo Microelectronics Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Olaplex Holdings, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity